Use of Serum Albumin Binding Peptides Conjugates for the Preparation of a Medicament
AssigneeAffibody AB
InventorNina Herne
Life of this patent
Estimating the term…
Loading patent…
AssigneeAffibody AB
InventorNina Herne
Estimating the term…
A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.
A method of preparing a medicament which elicits no or a reduced immune response upon administration to a mammal as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se, comprising combining a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal with a pharmaceutically acceptable carrier.
Method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the protein or a biologically active fragment or derivative thereof to at least one moiety capable of binding to a serum albumin of the mammal to form a conjugate, and administering the conjugate to the mammal.
Method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises forming a molecule including the protein or a biologically active fragment or derivative thereof and at least one moiety capable of binding to a serum albumin of the mammal and administering the molecule to the mammal.
(canceled)
(canceled)
An improvement in a method of administering a biologically active protein to a non-human or human mammal, wherein the improvement comprises administering a molecule comprising at least one moiety which is derived from the biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal, whereby the molecule elicits no or a reduced immune response as compared to a compound consisting of the biologically active protein per se.
(canceled)
(canceled)
A molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal, which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se.
A molecule selected from ZTaq4:1-ABD, ABD-Zher2:4, ABD-(Zher2:4)2, ABD-(Zher2:4)3, [ ,]ABD-(Zher2:4)4, (ZAβ3)2, ABD- and (ZAβ3)2.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.